Author Title Type [ Year(Desc)]
Filters: Author is Bonfim, Carmem  [Clear All Filters]
Arcuri LJavier, Nabhan SKanaan, Loth G, Atta EHallack, Oliveira M, Nichele S, Araujo Rde Castro, Bonfim C. A case series of post-transplant cyclophosphamide in unrelated donor hematopoietic transplantation for aplastic anemia. Biol Blood Marrow Transplant. 2020.
Marinho DHespanha, Ribeiro LLima, Nichele S, Loth G, Koliski A, Mousquer RToassa Gom, Funke VAraújo Mo, Page K, Fasth A, Pasquini R, et al. The challenge of long-term follow-up of survivors of childhood acute leukemia after hematopoietic stem cell transplantation in resource-limited countries: A single-center report from Brazil. Pediatr Transplant. 2020:e13691.
Arcuri LJavier, Nabhan SKanaan, Cunha R, Nichele S, Ribeiro AAlice Feit, Fernandes JFolloni, Daudt LEsteves, Rodrigues ALuiza Melo, Arrais-Rodrigues C, Seber A, et al. Impact of CD34 cell dose and conditioning regimen on outcomes after Haploidentical donor hematopoietic stem cell transplantation with post-transplant cyclophosphamide for relapsed/refractory severe aplastic anemia: Haploidentical HCT with PTCy for SAA. Biol Blood Marrow Transplant. 2020.
Arnold SD, Brazauskas R, He N, Li Y, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, et al. The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization. Biol Blood Marrow Transplant. 2020.
Fernandes JFolloni, Nichele S, Arcuri LJavier, Ribeiro L, Netto GZamperlini, Loth G, Rodrigues ALuiza Melo, Kuwahara C, Koliski A, Trennepohl J, et al. Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases. Biol Blood Marrow Transplant. 2020.